BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui
BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui
BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.